Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (560)	4/20/2001 4:53:13 PM
From: keokalani'nui	Respond to of 1784

WALTHAM, Mass., April 20 //PRNewswire Interactive Release/ -- Thermo Electron (NYSE: TMO) announced today that its Thermo Finnigan business has introduced three modified ion trap mass spectrometry products -- the PolarisQ, the LCQ(TM) Deca XP, and the LCQ(TM) Advantage -- for the German market. Thermo Finnigan modified its ion trap products for sale in Germany after a recent patent ruling in favor of its competitor, Bruker Daltonics. These products will be available immediately to German customers. (Photo: newscom.com "We are confident that our modifications address the concerns raised in the German court case," said Colin Maddix, president of Thermo Electron's Life Sciences sector. "While we were surprised by the ruling, our customers' needs come first. We moved quickly on the modifications to ensure that German customers who depend on our products can obtain them without interruption. These modified products, of course, continue to live up to our exacting standards of quality and our customers' high expectations." Mr. Maddix added, "Obviously, patent cases like these are very complicated, and the outcomes are subject to appeal. It's very difficult to predict how a court will rule. In fact, the same German court that recently found in favor of Bruker determined in separate proceedings last year that Bruker had infringed upon one of our key ion trap patents. On the other hand, a court in Boston ruled yesterday that Bruker had not infringed upon a claim of another patent. None of these court actions affects our ability to sell ion traps outside Germany. "Ultimately, this competition will take place in the marketplace. Since shipping our first ion trap product in 1983, we've been the leader in ion trap technology. We're confident that our ion traps are the highest throughput instruments -- the tool-of-choice for proteomic and other researchers. In the marketplace, we believe we have the clear advantage." SNIP